Today, the U.S. Food and Drug Administration approved Eucrisa (crisaborole), a topical treatment for children and adults with mild to moderate atopic dermatitis (AD). Eucrisa works differently than other topical treatments on the market. It is not a steroid or a topical calcineurin inhibitor.
In March 2017, the U.S. Food and Drug Administration (FDA) approved dupilumab (Dupixent). This medication is actually an antibiotic that can help lower inflammation, and it's used for the treatment of moderate-to-severe eczema.
These breakthroughs are leading to new treatments. The U.S. Food and Drug Administration (FDA) has approved two medications, and more than 40 possible
Patients with severe eczema have been given hope of a breakthrough with biologics â€” a new class of drugs which reduce inflammation and break the .
Î¤he results of two large clinical trials of a new drug offers hope to people with an uncontrolled, moderate-to-severe form of the disease, atopic dermatitis, which is .
The disease is characterized by an itching, oozing rash that can cover almost all of the skin. The constant itch, to say nothing of the disfigurement, can be so .
A new ointment called tacrolimus which is based on an anti-rejection drug is set to. The trial of children with moderate to severe atopic eczema – eczema in .